| 764108 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.523 |
Shum Elaine, Reilley Matthew, Najjar Yana, Daud Adil, Thompson John, Baranda Joaquina, Donald Harvey R, Shields Anthony, Cohen Ezra, Pant Shubham, Leidner Rom, Mita Alain, Cohen Roger, Chmielowski Bartosz, Stein Mark, Hu-Lieskovan Siwen, Fleener Catherine, Ding Ying, Bao Lei, Chollate Sowmya, Shorr Jolene, Clynes Raphael, Hickingbottom Barbara |
| 764107 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
522 Transcriptomic changes in cancer patients treated with immune-checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.522 |
Shek Dmitrii, Gao Bo, Lai Joey, Yoon Won-Hee, Moujaber Tania, Nagrial Adnan, Carlino Matteo, Read Scott, Ahlenstiel Golo |
| 764106 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
521 GEN-009, a personalized neoantigen vaccine candidate, elicits diverse and durable immune responses associated with clinical efficacy outcomes |
2021-11-01 |
10.1136/jitc-2021-sitc2021.521 |
Shainheit Mara, Bicak Ece, Golshadi Masoud, Santone Gabriella, Shukor Syukri, Tjon Emily, Xue Li, Davis Thomas, Flechtner Jessica |
| 764105 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
447 Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.447 |
Kumar Shaji, Mamuye Admasu, Dabovic Kristina, Wang Jingyuan, Anand Banmeet, Yuet Amy, Dholaria Bhagirathbhai, Roy Vivek |
| 764104 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
210 A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immunotherapies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.210 |
Gillig Marc, Lambert Graeme, Sonntag Donna, Ohri Rachit, Cahoon Jason, Shemesh Avishai, Amoor Rafet |
| 764103 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
921 Comparison of PI3K/AKT/mTOR pathway profiles amongst three immune phenotypes classified by artificial intelligence-powered H&E analyzer in non-small cell lung cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.921 |
Cho Hyung-Gyo, Lee Grace, Kim Hye Sung, Song Sanghoon, Paeng Kyunghyun, Ock Chan-Young, Chae Young Kwang |
| 764102 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
915 Molecular characterization of AXL in solid tumor malignancies using real-world data |
2021-11-01 |
10.1136/jitc-2021-sitc2021.915 |
Si Han, Jure-Kunkel Maria, Pencheva Nora, Xu Steven, Higgs Brandon, Sasser Kate, Hamadeh Hisham, Agius Phaedra, Grigaityte Kristina |
| 764101 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
914 Loss of LKB1 is associated with resistance to IFN-gamma and T cell killing in non-small cell lung cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.914 |
Reuben Alexandre, Jiang Peixin, Nie Hui, Cobo Ana Galan, Dang Minghao, Qian Yu, Frank Meredith, Blitz Emily, Hamdi Haifa, Denning Warren, Nilsson Monique, Poteete Alissa, Shen Li, Wang Qi, Guijarro Irene, Nichols Keri, Khairullah Roohussaba, Zhang Jiexin, Skoulidis Ferdinandos, Wang Jing, Wang Linghua, Heymach John |
| 764100 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
913 A murine gastric cancer YTN16 model for the rational design of combination immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.913 |
Nagaoka Koji, Sun Changbo, Kobayashi Yukari, Kakimi Kazuhiro |
| 764099 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
912 Preferential recognition of neoantigens over non-canonical peptides in cancer patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.912 |
Lozano-Rabella Maria, Garcia-Garijo Andrea, Palomero Jara, Erhard Florian, Martín-Liberal Juan, Matos Ignacio, Gartner Jared, Rosenberg Steven, Ghosh Michael, Canals Francesc, Vidal August, Piulats Josep Maria, Matias-Guiu Xavier, Braña Irene, Muñoz Eva, Garralda Elena, Schlosser Andreas, Gros Alena |
